Physician profile
Gary M Fowler
NPI 1073503405
$3,080.37
in general payments reported to CMS, 2019-2025
28 companies · $707 in 2025
The $707 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $547 · 2021: $374 · 2022: $232 · 2023: $429 · 2024: $294 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $519.85 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $410.97 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $309.59 | 2019-2021 | |
| Lilly USA, LLC | $297.53 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals LP | $287.02 | 2019-2025 | Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $282.16 | 2024-2025 | Gemtesa |
| Pfizer INC. | $134.23 | 2020-2024 | |
| Ibsa Pharma INC. | $113.82 | 2021-2025 | Tirosint, Tirosint, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.12 | 2019-2025 | Xifaxan |
| Abbvie INC. | $93.81 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $85.52 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.83 | 2025 | |
| Exact Sciences Corporation | $48.77 | 2025 | Cologuard Collection Kit |
| Radius Health, INC. | $44.61 | 2019-2020 | |
| Amgen INC. | $43.74 | 2019-2025 | Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $31.68 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $24.48 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $22.23 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.83 | 2020 | |
| Ardelyx, INC. | $18.98 | 2025 | Ibsrela |
| Corcept Therapeutics | $18.72 | 2025 | Korlym |
| Atland Pharmaceuticals, LLC | $16.19 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Xeris Pharmaceuticals, INC. | $14.80 | 2024 | Gvoke Hypopen |
| Adlon Therapeutics L.P. | $14.66 | 2020 | |
| Dexcom, INC. | $13.56 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.00 | 2020 | |
| Phadia US INC. | $10.90 | 2019 | |
| Axsome Therapeutics, INC. | $7.77 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.